Replies to post #65582 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

I simply thought it was an interesting case study, especially the part about raising funds with no discount to market. Of course, the Alzheimer's market alone is much larger than the market ACAD was serving so there is no direct comparison.

Also, because of the fact that 2-73 is the only drug that's ever shown an improvement in cognition with Alzheimer's I expect trial design to be much simpler and less expensive than anticipated.